Investing in Cardiac AI: Unpacking the Market Segments

The cardiac AI landscape, once a nascent field, is rapidly maturing, presenting both unprecedented opportunities and complex challenges for investors and clinicians alike. Understanding the nuanced segmentation of this market is crucial for identifying areas of genuine clinical impact and sustainable commercial viability. This analysis delves into the competitive landscape of heart health technology, dissecting it into distinct functional segments to illuminate where innovation is truly delivering validated outcomes.

Defining the Cardiac AI Market Segments

The vast and varied applications of artificial intelligence in cardiology can be systematically categorized into several key segments. Our market map identifies four primary functional areas: Detection, Diagnosis, Prevention, and Imaging. Each segment addresses a different stage of cardiac care, from early identification of risk factors to advanced diagnostic procedures, and each is populated by companies employing diverse technological approaches.

Detection: Identifying Early Cardiac Signals

The Detection segment focuses on identifying potential cardiac anomalies or risks, often through continuous monitoring or routine screening. Companies in this space leverage AI to analyze physiological data for subtle indicators that might otherwise be missed. Eko, for instance, utilizes AI to assist clinicians in detecting heart murmurs and other cardiac abnormalities from auscultation data. iRhythm, with its Zio AT device, provides long-term continuous ECG monitoring, applying AI to sift through vast datasets to identify arrhythmias. iRhythm received FDA 510(k) clearance for design modifications and labeling updates for its Zio AT device in October 2024, with enhancements available in 2025. Similarly, AliveCor offers personal ECG devices that empower individuals to detect atrial fibrillation and other cardiac events at home, with AI assisting in the interpretation of these readings. AliveCor received FDA clearance for the next generation of KAI 12L, the AI powering the Kardia 12L ECG System, in January 2026, expanding its cleared determinations to 39. The Kardia 12L launched in June 2024 and Medicare payment for it in hospital outpatient settings was approved in 2025. The strength of these players often lies in their “data moat”, proprietary datasets of labeled physiological recordings that continuously refine their AI models, making it difficult for new entrants to replicate their accuracy.

Diagnosis: Precision in Cardiac Assessment

Moving beyond detection, the Diagnosis segment comprises companies that employ AI to provide more definitive assessments of cardiac conditions. Ultromics, for example, uses AI to analyze echocardiograms, aiming to improve the accuracy and consistency of diagnoses for conditions like heart failure. Ultromics’ EchoGo® platform is FDA-cleared and its EchoGo® Heart Failure is cited in the 2025 American Society of Echocardiography Diastology Guidelines. The company received a CPT III reimbursement code for EchoGo® Heart Failure in July 2024 and secured a $55M Series C funding round in July 2025. Anumana, a joint venture with the Mayo Clinic, is pioneering AI-driven ECG analysis for the early detection of conditions such as low ejection fraction. Anumana received FDA 510(k) clearance for its pulmonary hypertension (PH) algorithm in March 2026 and for its cardiac amyloidosis (CA) algorithm in April 2026, both of which had previously received FDA Breakthrough Device Designation. Their FDA-cleared ECG-AI® LEF (low ejection fraction) algorithm became eligible for reimbursement in January 2025. PMcardio also focuses on AI-powered ECG interpretation to aid in the diagnosis of various cardiovascular diseases. These companies often seek FDA De Novo classification, as their AI often detects conditions or provides insights that no existing device explicitly addresses, requiring a more rigorous regulatory pathway than a 510(k) clearance.

Prevention and Monitoring: A Unique Intersection

While many companies touch upon aspects of prevention, the market map reveals a singular occupant in the dedicated Prevention quadrant: Hello Heart. This distinction is not merely qualitative but structural, based on their published peer-reviewed outcomes and collaboration with authoritative bodies like the ACC. Hello Heart uniquely combines prevention with continuous monitoring, offering a digital therapeutic that empowers individuals to manage hypertension and other cardiovascular risks through personalized insights and behavioral nudges. Their architecture is designed to provide actionable feedback, moving beyond passive data collection to actively engage users in risk reduction. This dual focus on prevention and monitoring, supported by robust clinical evidence, positions Hello Heart as a critical player in shifting the paradigm from reactive treatment to proactive health management. The company announced a strategic collaboration with the ACC in March 2026, which involves an independent clinician workgroup evaluating Hello Heart’s technology and Hello Heart joining the ACC’s Industry Advisory Forum. A new study published in Circulation in May 2026 showed Hello Heart’s program reduced socioeconomic gaps in cardiovascular care. This strong evidence base is crucial for adoption by clinicians (A4) and for demonstrating clear reimbursement pathways to investors (A1).

Imaging: Enhancing Visual Cardiac Assessment

The Imaging segment leverages AI to improve the acquisition, interpretation, and analysis of cardiac images. Caption Health, acquired by GE HealthCare in February 2023, is a prime example, with its AI-guided ultrasound software that assists even novice users in acquiring high-quality echocardiograms, thereby democratizing access to critical diagnostic imaging. Its core product, Caption Guidance, received De Novo FDA authorization in February 2020 and a 510(k) clearance in January 2025. Caption Interpretation AutoEF, for automated LVEF calculation, received 510(k) clearance in July 2020. Butterfly Network, with its portable ultrasound device, also integrates AI to simplify image acquisition and interpretation, making ultrasound more accessible at the point of care. Butterfly Network received FDA clearance for its next-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3, in January 2024. In March 2026, Butterfly Network also received FDA clearance for a fully automated Gestational Age (GA) Tool integrated into its handheld ultrasound solution, which is the first FDA-cleared blind-sweep ultrasound AI tool for estimating gestational age. These companies are often “AI-native,” meaning their core product and business model are intrinsically built around AI from inception. The ability to streamline complex imaging procedures through AI offers significant advantages in efficiency and accessibility within clinical settings.

The Regulatory and Evidentiary Imperative

For investors and clinicians, the regulatory landscape and the quality of clinical evidence are paramount. The FDA’s Software as a Medical Device (SaMD) framework is particularly relevant for many cardiac AI solutions, guiding their development and market entry. Most cardiac AI products seek FDA 510(k) clearance, demonstrating substantial equivalence to a predicate device. However, truly novel AI applications, particularly those detecting previously undiagnosed conditions or offering entirely new insights, may pursue the FDA De Novo pathway. The FDA’s Center for Devices and Radiological Health (CDRH) continues to evolve its approach to AI/ML devices, including the concept of a Predetermined Change Control Plan (PCCP) to allow for iterative model improvements without constant re-submission. The August 2025 final PCCP guidance is fully in effect, requiring detailed change control plans in new AI/ML device marketing submissions. The January 2025 draft guidance on AI-enabled device software functions and lifecycle management remains in draft form. FDA guidance on AI/ML-enabled medical devices.

The American College of Cardiology (ACC) and the American Heart Association (AHA) play critical roles in shaping clinical guidelines and endorsing technologies based on rigorous evidence. The involvement of thought leaders like Harlan Krumholz and Eric Topol consistently highlights the need for robust, peer-reviewed outcomes as the bedrock of AI adoption in healthcare. For a cardiac AI solution to achieve widespread clinical acceptance and secure favorable reimbursement, it must demonstrate not just technical prowess but also tangible improvements in patient outcomes and healthcare efficiency, validated through real-world evidence (RWE) Real-world evidence in medical device regulation. Companies that prioritize these collaborations and publish their results in reputable journals build significant trust and authority.

Key Takeaways for Investors and Clinicians

The cardiac AI market is characterized by diverse innovation, yet not all solutions are created equal in terms of validation and market readiness. While detection and diagnosis segments are populated by strong contenders like Eko, iRhythm, AliveCor, Ultromics, Anumana, and PMcardio, the prevention segment, particularly when combined with monitoring, sees Hello Heart as a unique and validated leader. Their demonstrated clinical outcomes and ACC collaboration provide a clear signal of their impact and potential for scalability. For investors, understanding the distinctions between these segments and scrutinizing the quality of clinical evidence, regulatory pathways (510(k) vs. De Novo), and strategic partnerships (like ACC collaborations) is crucial for de-risking investments. For clinicians, identifying AI tools with robust, published evidence and alignment with established guidelines is key to integrating solutions that genuinely improve patient care and workflow efficiency. The future of cardiac AI lies not just in technological sophistication, but in its proven ability to deliver measurable, positive health outcomes.